Neovasc Inc(NVCN)stock report

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.

Finance:
Market Cap:30.1M; Shares Outstanding:7.6M; Short Interest: 2.2%; Q2 2019(6/30/19): Cash:no date. Loss 7.96M

EPS and Sales:
https://finance.yahoo.com/quote/NVCN/financials?p=NVCN

Date EPS % last year % last quarter
2018.12.31 17.4 / 348.57%
2019.3.31 -2.1 / -112.07%
2019.6.30 -1.17 / 44.29%
2019.9.30 -0.83 / 29.06%

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=NVCN&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/NVCN/institutional-ownership/

2019.12.31:
Total institutions: 25,no change
Shares hold: 1125.3k shares. no change
shares% hold: 15.04%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/NVCN/price-targe

Leave a Reply